Developing vaccines against epidemic-prone emerging infectious diseases Entwicklung von Impfstoffen gegen neu auftretende Infektionskrankheiten mit epidemischem Potenzial

Abstract

'Raúl Gómez Román' 'Alison Bettis' 'Solomon Abebe Yimer' 'Céline Gurry' 'Svein R. Andersen' 'Debra Yeskey' 'Henshaw Mandi' 'Arun Kumar' 'Johan Holst' 'Carolyn Clark' 'Jakob P. Cramer' 'John-Arne Røttingen' 'Richard Hatchett' 'Melanie Saville' 'Gunnstein Norheim'] Today’s world is characterized by increasing population density, human mobility, urbanization, and climate and ecological change. This global dynamic has various effects, including the increased appearance of emerging infectious diseases (EIDs), which pose a growing threat to global health security. Outbreaks of EIDs, like the 2013-2016 Ebola outbreak in West Africa or the current Ebola outbreak in Democratic Republic of the Congo (DRC), have not only put populations in low- and middle-income countries (LMIC) at risk in terms of morbidity and mortality, but they also have had a significant impact on economic growth in affected regions and beyond. The Coalition for Epidemic Preparedness Innovation (CEPI) is an innovative global partnership between public, private, philanthropic, and civil society organizations that was launched as the result of a consensus that a coordinated, international, and intergovernmental plan was needed to develop and deploy new vaccines to prevent future epidemics. CEPI is focusing on supporting candidate vaccines against the World Health Organization (WHO) Blueprint priority pathogens MERS-CoV, Nipah virus, Lassa fever virus, and Rift Valley fever virus, as well as Chikungunya virus, which is on the WHO watch list. The current vaccine portfolio contains a wide variety of technologies, ranging across recombinant viral vectors, nucleic acids, and recombinant proteins. To support and accelerate vaccine development, CEPI will also support science projects related to the development of biological standards and assays, animal models, epidemiological studies, and diagnostics, as well as build capacities for future clinical trials in risk-prone contexts.